ReutersReuters

Patritumab Deruxtecan Biologics License Application For Patients With Previously Treated Locally Advanced Or Metastatic Egfr-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn

Refinitiv閱讀少於1分鐘
  • PATRITUMAB DERUXTECAN BIOLOGICS LICENSE APPLICATION FOR PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC EGFR-MUTATED NON-SMALL CELL LUNG CANCER VOLUNTARILY WITHDRAWN

登入或建立一個永久免費帳戶來閱讀此新聞